^
Association details:
| Biomarker: | Chr t(3;11) + KMT2A-LARS2 fusion |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency
Published date:
04/27/2021
Excerpt:
...9-year-old boy...diagnosed with t(3;11)+ (KMT2A-LARS2) BCP-ALL 9 years after his transplant. He received a 4-drug induction followed by blinatumomab for persistent MRD as a chemotherapy-sparing bridge to transplant and achieved an MRD- remission.
DOI:
10.1182/bloodadvances.2021004284
